I'm also convinced HSP90 is a very promising target, but my concern is that its activity may not properly emerge as a single agent. If this is correct, it makes development much harder, and means that any promising candidate really belongs in a big pharma program rather than in a small company program.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.